Pemphigus Vulgaris Market

Pemphigus Vulgaris: Introduction

• Pemphigus vulgaris is an uncommon, persistent autoimmune disorder that causes blisters on the skin and mucous membranes. It is regarded as the most common variant of the autoimmune blistering disease pemphigus. In pemphigus vulgaris, the immune system accidentally produces antibodies against desmogleins, a type of protein required for skin cell attachment.
• This antibody attack causes blisters and separates skin layers. Blisters can arise anywhere on the body, although they are most commonly found in the mouth, throat, scalp, face, chest, groin, and armpits. The increasing awareness of diseases is projected to fuel market expansion.
• Pemphigus vulgaris is a persistent immune system illness affecting a small number of people. Blisters form on the skin and in the mouth as a result. Although treatment and diagnosis might aid in control, if the condition causes severe symptoms.
• Pemphigus is a chronic, severe autoimmune bullous disease caused by autoantibodies that target keratinocyte adhesion molecules. The issue must be treated for around two to three years.

Rising cases of Immune System Malfunction is expected to drive the Pemphigus Vulgaris Market

• The increased number of cases of immune system dysfunction, in which antibodies assault the proteins that hold skin cells together, is boosting the pemphigus vulgaris market. Furthermore, the increasing use of numerous medications such as nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors, penicillamine, and others, which aid in the start of the disease, is driving market expansion. Besides, the widespread use of immunosuppressive medicines regarding corticosteroids to manage the immune system and prevent the production of new blisters bodes well for the industry.
• In the United Kingdom, the reported incidence is 0.68 cases per 100,000 individuals each year. The occurrence varies greatly by ethnic background, with Middle Eastern and Jewish people are more likely to be impacted than those from Western Europe. The fifth and sixth decades of life are the most common onset years, and both the sexes are equally affected. PV is connected with an increase in overall mortality, primarily due to the immunosuppressive treatment necessary with respiratory tract infections and septicemia, which are frequently recorded as causes of death.

Rising Drug Approvals for the Treatment of Pemphigus Vulgaris is Attributed to Drive Overall Pemphigus Vulgaris Market

• Rise in the number of approvals for the treatment of Pemphigus Vulgaris (PV) are noticeably driving the pemphigus vulgaris market by increasing the availability of effective therapies, and improving patients’ access to novel treatments.
• In September 2024, a Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease. The study found that Dupixent patients achieved durable illness remission five times more often as compared to placebo patients. Sustained disease remission was defined as complete clinical remission with completion of oral corticosteroid (OCS) taper by week 16, no relapse, and no rescue drug use over the 36-week treatment period.

By Drug Class, the Monoclonal Antibody segment accounted for the largest share of the pemphigus vulgaris industry

• The monoclonal antibody (mAb) medication class leads the Pemphigus Vulgaris (PV) market due to its effectiveness, specific mechanism of action, minimal side-effects, and increasing regulatory approvals. Corticosteroids and immunosuppressants were previously used to treat PV, but long-term treatment has been linked to serious adverse effects such as infections, osteoporosis, diabetes, and cardiovascular disease. The advent of monoclonal antibodies revolutionized the medical field by providing better and safer therapy alternatives.
• One of the main reasons for this growth has been the FDA approval and extensive use of Rituximab (MabThera/Rituxan). Rituximab, a monoclonal anti-CD20 antibody, was the first FDA-approved biologic drug used for PV in 2018. It selectively reduces B lymphocytes, which are responsible for generating the disease-producing autoantibodies. Clinical trials have proven that Rituximab offers more durable remission, less relapse, and an improved safety profile as compared to conventional therapy. Rituximab's success has been followed by additional funding of monoclonal antibody research in PV.
• These are some of the factors contributing in the growth of the monoclonal antibody drug class market segment in the overall Pemphigus Vulgaris Market.

North America to Lead the Pemphigus Vulgaris Market

• Government agencies are engaged in research and development activities regarding novel medications for pemphigus vulgaris treatment. For example, the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the United States Department of Health and Human Services (HHS), is undertaking a Phase 1 trial to evaluate the use of Polyclonal T regulatory cells in the treatment of pemphigus vulgaris. The investigation began in September 2017 and was expected to be finished by September 2020.
• Argenx SE, a biopharmaceutical firm based in tThe Netherlands, is conducting a Phase-2 clinical trial to assess the efficacy of ARGX-113 for the treatment of pemphigus vulgaris. The study is expected to be completed by August 2019. ARGX-113 is an antibody Fc fragment (crystalllizable fragment) that works on the neonatal Fc Receptor, which is implicated in the IgG half-life extending pathway and ultimately leads to autoantibody persistence, hence mediating autoantibody elimination from the system. As a result, the increasing number of clinical studies to find new therapeutics for pemphigus vulgaris is likely to drive growth of pemphigus vulgaris treatment market across Europe during the forecast period.

Key Players Operating in the Global Pemphigus Vulgaris Market

The major players operating in the global market are focusing on advancements in research and development to meet the rising demand for Pemphigus Vulgaris treatment. Moreover, service providers are entering into partnerships for the development of innovative products.

Key players operating in the global pemphigus vulgaris market include:

• Sanofi
• Regeneron Pharmaceuticals Inc.
• Dr. Reddy’s Laboratories Ltd.
• Alexion Pharmaceuticals
• Argenx
• Cabaletta Bio, Inc.
• Daewoong Pharmaceutical
• Declion Pharmaceuticals
• HanAll Biopharma
• Gilead Sciences, Inc.
• Other Prominent Players

Market Segmentation

• By Drug Class:
  • Corticosteroids
  • Immunosuppressant
  • Analgesics
  • Monoclonal Antibody
  • Cholinergic agonists
  • Others (Late Phase Drugs, etc.)
• By Route of Administration:
  • Oral
  • Topical
  • Parenteral
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa